Swedish biopharma Anocca raised approximately $46 million in financing which it will use to progress its gene-edited T-cell receptor-engineered T cell (TCR-T) therapy targeting mutant KRAS in pancreatic cancer through early-stage clinical development.
Anocca’s VIDAR-1 clinical program is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase 1/2 studies. Recruitment is now open for phase 1 of the multi-center trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and the Netherlands.
Anocca uses programmable human cells to recreate and manipulate T cell immunity. The company’s proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalized treatments for the broad patient populations.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!